32.32

0.03% 0.010

Pre-market: 32.43 0.11 +0.34%

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $32.32, with a volume of 237.82K. It is up +0.03% in the last 24 hours and down -0.09% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$32.31

Open:

$31.97

24h Volume:

237.82K

Relative Volume:

0.62

Market Cap:

$987.36M

Revenue:

$339.92M

Net Income/Loss:

$-12.83M

P/E Ratio:

-75.25

EPS:

-0.4295

Net Cash Flow:

$4.52M

1W Performance:

-1.01%

1M Performance:

-0.09%

6M Performance:

+21.50%

1Y Performance:

+40.89%

1-Day Range:

$31.44

$32.70

1-Week Range:

$31.44

$33.58

52-Week Range:

$17.72

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1069)

Industry

Diagnostics & Research (49)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

942

Twitter

@castlebio

Next Earnings Date

2026-11-02

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, NTRA, IQV, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	32.32	987.36M	339.92M	-12.83M	4.52M	-0.4295
TMO Thermo Fisher Scientific Inc	603.18	223.02B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	200.53	140.97B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	326.14	47.01B	2.50B	-226.32M	71.51M	-1.6412
IQV Iqvia Holdings Inc	257.30	42.35B	16.63B	1.39B	2.12B	8.0674
A Agilent Technologies Inc	143.12	40.35B	7.23B	1.41B	1.09B	4.979

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Sep 10, 2026

Castle Biosciences, Inc.JAAD Publication Shows Improved Performance of DecisionDx-SCC - marketscreener.com

Sep 10, 2026

Responsive Playbooks and the CSTL Inflection - Stock Traders Daily

Sep 10, 2026

Sep 09, 2026

A skin-cancer test found its highest-risk group was 10.7 times more likely to develop cancer spread - Stock Titan

Sep 09, 2026

Sep 08, 2026

SciBase receives additional order from Castle Biosciences, advancing the collaboration - Yahoo Finance

Sep 08, 2026

Bank of New York Mellon Corp Invests $2.34 Million in Castle Biosciences, Inc. $CSTL - MarketBeat

Sep 08, 2026

Sep 05, 2026

Castle Biosciences Stock Price Forecast. Should You Buy CSTL? - StockInvest.us

Sep 05, 2026

Sep 04, 2026